Weekly Digest - Mar 2024

Weekly Digest - Mar 2024

12 Mar 2024: Pfizer eyes Adcetris Expansion into Large B-Cell Lymphoma following successful trial

  • Adcetris, a Pfizer’s ADC, secures the first pivotal trial victory from the legacy Seagen portfolio post-merger, marking a significant milestone
  • In the phase 3 trial ECHELON-3, Adcetris, a SOC for cHL, demonstrates efficacy in DLBCL, a prevalent form of n-HL, suggesting potential therapeutic versatility
  • In ECHELON-3, Adcetris triplet meets the overall survival endpoint, significantly delaying tumor progression compared to the two-drug regimen (lenalidomide and rituximab)
  • The FDA first approved this CD30-directed ADC in 2011, currently indicated for classical Hodgkin lymphoma and specific T-cell lymphomas

For full story click here

Share this

Facebook
fb-share-icon
Twitter
Tweet
LinkedIn
Share
Home